Check for updates

OPEN ACCESS

EDITED BY Raúl Ferrer-Peña, CSEU La Salle, Spain

REVIEWED BY Alfredo Lerín Calvo, La Salle Centro Universitario, Spain Francisco Gurdiel-Álvarez, Rey Juan Carlos University, Spain

*CORRESPONDENCE Seoyon Yang ⊠ seoyonyang@gmail.com

RECEIVED 18 October 2023 ACCEPTED 06 December 2023 PUBLISHED 20 December 2023

CITATION

Chang MC, Briand M-M, Boudier-Revéret M and Yang S (2023) Effectiveness of transcranial alternating current stimulation for controlling chronic pain: a systematic review. *Front. Neurol.* 14:1323520. doi: 10.3389/fneur.2023.1323520

COPYRIGHT

© 2023 Chang, Briand, Boudier-Revéret and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Effectiveness of transcranial alternating current stimulation for controlling chronic pain: a systematic review

Min Cheol Chang¹, Marie-Michèle Briand^{2,3,4}, Mathieu Boudier-Revéret^{4,5} and Seoyon Yang^{6*}

¹Department of Rehabilitation Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea, ²Division of Trauma, Research Center, Hòpital du Sacré-Cœur de Montréal, CIUSSS du Nord-de-l'Île-de-Montréal, Montréal, QC, Canada, ³Department of Physical Medicine and Rehabilitation, Hôpital du Sacré-Cœur de Montréal, CIUSSS du Nord-de-l'Île-de-Montréal, Montréal, QC, Canada, ⁴Faculty of Medicine, Université de Montréal, Montréal, QC, Canada, ⁵Department of Physical Medicine and Rehabilitation, University of Montreal Health Center, Montréal, QC, Canada, ⁶Department of Rehabilitation Medicine, School of Medicine, Ewha Woman's University Seoul Hospital, Seoul, Republic of Korea

Background: Chronic pain is common, disruptive, and often treatmentresistant. Hence, researchers and clinicians seek alternative therapies for chronic pain. Transcranial alternating current stimulation (tACS) is an emerging neuromodulation technique that non-invasively modulates neural oscillations in the human brain. tACS induces pain relief by allowing the neural network to restore adequate synchronization. We reviewed studies on the effectiveness of tACS in controlling chronic pain.

Methods: The PubMed, SCOPUS, Embase, and Cochrane Library databases were systematically searched for relevant studies published until December 6, 2023. The key search phrase for identifying potentially relevant articles was [(Transcranial Alternating Current Stimulation OR tACS) AND pain]. The following inclusion criteria were applied for article selection: (1) studies involving patients with chronic pain; (2) tACS was applied for controlling pain; and (3) follow-up evaluations were performed to assess the degree of pain reduction after the application of tACS.

Results: We identified 2,330 potentially relevant articles. After reading the titles and abstracts and assessing eligibility based on the full-text articles, we included four articles in our review. Among the included studies, tACS was used for fibromyalgia in one study, low back pain (LBP) in two studies, and migraine in one study. In the study on fibromyalgia, it did not show a better pain-reducing effect of tACS compared with sham stimulation. Two studies on LBP showed conflicting results. In migraine, tACS showed a positive pain-reducing effect 24–48 h after its application.

Conclusion: There is insufficient research to draw a conclusive judgment on the effectiveness of tACS in controlling chronic pain. More studies across various chronic pain-related diseases are required for a definitive conclusion.

KEYWORDS

transcranial alternating current stimulation, chronic pain, fibromyalgia, low back pain, migraine, treatment, review

Introduction

Chronic pain is pain that persists for more than 3 months or after complete healing, which is a leading cause of disability and disease worldwide (1, 2). Approximately 20% of the adult population experiences chronic pain, with 8% of individuals reporting severe pain that disrupts their life and work activities (3). To manage chronic pain, various therapeutic methods have been applied, including physical therapy, psychotherapy, medication, procedures, and surgery (1, 2). However, despite these treatments, chronic pain often remains uncontrolled.

The brain plays a fundamental role in the processing of pain (4). Several previous studies using electroencephalography (EEG) and magnetoencephalography (MEG) demonstrated that chronic pain is closely associated with abnormal neuronal oscillations (5–8). The peak frequency of neuronal oscillations measured by EEG or MEG was lower in patients with chronic pain compared with that of healthy controls (5–8). Specifically, changes in neural oscillations at gamma (30–100 Hz) frequencies in prefrontal brain area are related to chronic pain (9). The modulation of neural oscillations has been suggested to be a promising novel therapeutic approach for controlling chronic pain.

Transcranial alternating current stimulation (tACS) is an emerging neuromodulation technique that non-invasively modulates neural oscillations in the human brain (10–12). During the application of tACS, a weak alternating sinusoidal current is administered to the scalp with the aim of synchronizing neural oscillations at the stimulation frequency, thereby enhancing their amplitude and causing a new balance by forcing the neural network to restore adequate synchronization (10–12). This neural modulation by tACS was proposed to induce pain relief.

Thus far, some clinical trials have been conducted to investigate whether tACS has a pain-reducing effect in patients with chronic pain (13–17). In this study, we review previous studies on the effectiveness of tACS in controlling chronic pain and integrate their results to draw a comprehensive conclusion on the therapeutic possibility of tACS for pain reduction.

Methods

This systematic review conformed to the recommendations of the Preferred Reporting Items for Systematic Review and Meta-analysis. The protocol was registered on the international platform of registered systematic reviews protocols (registration number: INPLASY2023120012).

The population, intervention, comparison, and outcome (PICO) setting of the current systematic review was as follows: P: patients with chronic pain; I: tACS combined with or without other therapies for controlling pain; C: placebo or sham stimulation; and O: pain intensity. Two authors (MC and SY) searched for relevant studies published until December 6, 2023, in the PubMed, SCOPUS, Embase, and Cochrane Library databases (Supplementary material 1). The key search phrase for identifying potentially relevant articles was [(Transcranial Alternating Current Stimulation OR tACS) AND pain]. The following inclusion criteria were applied for the selection of articles: (1) patients with chronic pain; (2) tACS was applied for controlling pain; and (3) follow-up evaluations were performed after

tACS stimulation to assess the degree of pain reduction after the application of tACS. We excluded the following studies: (1) review articles; (2) animal studies; and (3) conference abstracts or presentations.

After duplicate publications were deleted, two reviewers (MC and SY) independently evaluated potentially eligible studies that were identified by our search. Articles were screened for eligibility based on a review of the title and abstract, and disagreements were resolved by consensus. The full texts of eligible articles were accessed and read independently by the two reviewers (MC and SY).

The risk of bias of selected studies was evaluated using the criteria described in the Cochrane Handbook for Systematic Reviews of Interventions to assess potential bias (18). The domains to evaluate the risk of bias were as follows: (1) random sequence generation and allocation concealment (selection bias); (2) blinding of participants and personnel (performance bias); (3) blinding of outcome assessment (detection bias); (4) incomplete outcome data (attrition bias); (5) selective reporting (reporting bias); and (6) other biases. Two independent reviewers performed these evaluations (MC and SY), and discrepancies were resolved through discussion.


Results

Search results

A total of 2,405 articles were identified using the search terms. Of these, 740 duplicates were excluded from further analysis. After reading the titles and abstracts, 1,653 articles were excluded because they did not meet the inclusion criteria. Subsequently, 12 full-text articles were retrieved to verify study eligibility, and a total of four publications were finally included in this review (Figure 1) (13, 14, 16, 17). These four publications were all randomized controlled trials (RCTs) (13, 14, 16, 17). Among these four studies, two were conducted under a randomized, double-blind, crossover design (13, 17). Table 1 presents the characteristics of the included articles, and Table 2 presents the application methods for tACS and combined treatments with tACS. Among four included studies, tACS was applied for fibromyalgia in one study (16), low back pain (LBP) in two studies (13, 17), and migraine in one study (14).

Fibromyalgia

In 2022, Lin et al. conducted an RCT to evaluate the effect of tACS on the left primary motor cortex (M1) for the management of chronic pain from fibromyalgia (16). Thirty-eight patients having a history a widespread pain with \geq 3 months duration were recruited and randomly allocated to the tACS (n = 19) and sham stimulation (n = 19) groups. tACS was conducted with a daily session of 20 min of stimulation of 1 mA at 50 Hz (duty cycle with an on time of 2 s and off time of 8 s) over the left M1 (C3 position in the 10/20 system for the EEG electrode positions) for 10 sessions in 2 weeks. For the administration of the electrical current, a 4×1 ring electrode configuration was used. The pain severity and physical function were assessed using the numeric rating scale (NRS) and the fibromyalgia impact questionnaire (FIQ) at baseline and after 2 weeks of tACS treatment. Additionally, the Beck Anxiety Inventory, Beck Depression



Inventory-II, and Pittsburgh Sleep Quality Index (PSQI) were checked. During the study, one patient in the tACS group and two in the sham stimulation group dropped out. After 10 sessions of tACS and sham stimulation, there were no significant differences in the changes in all the measurements between the groups. After tACS, various adverse events, including headache, scalp pain, stinging, itch, burning sensation, drowsiness, and difficulty concentrating, were reported. However, the severity of all the adverse events was mild, and the occurrence rate was not different from the sham stimulation group.

Low back pain

In 2019, Ahn et al. (13) performed a randomized, double-blind, crossover design study to investigate the effect of tACS on controlling LBP. They recruited 20 patients with chronic LBP persisted at least 5 months and randomly allocated them into two groups (tACS and sham stimulation groups). After the first session was completed, all the patients had a washout interval of 1-3 weeks. They were then crossed over to the other groups and had a second session. Two stimulating electrodes ($5 \text{ cm} \times 5 \text{ cm}$ each) were placed at the bilateral

frontal lobe (F3 and F4) and delivered a sinusoidal waveform with 1 mA amplitude for 40 min. The return electrode $(5 \text{ cm} \times 7 \text{ cm})$ was placed at Pz (medial parietal region). At pretreatment and after completing each session, the Defense and Veterans Pain Rating Scale (DVPRS, from 0 to 10, 0 = no pain and 10 = worst imaginable pain, similar to the NRS), Oswestry Disability Index (ODI), and enhancement of alpha oscillation were measured. After tACS, the pain severity measured by DVPRS was significantly reduced compared to sham stimulation, but ODI was not. The increase in alpha oscillations was significantly higher after tACS compared to sham stimulation.

In the same year, Prim et al. (17) conducted a randomized, double-blind, crossover design study in 20 patients with chronic LBP (pain duration: at least 6 months). The included patients were divided into two groups (10 patients per group). The schedule for the application of tACS, areas that place the electrodes, and electrode type were the same as in Ahn et al.'s study on the forehead. Prim et al. defined the responders as patients who had a decrease of ≥ 2 points on the DVPRS after completing the stimulation session. Twice as many patients reported being responders after tACS treatment vs. after sham stimulation, but no significant difference was found. They also checked the degree of adverse effects, including headache, neck pain, scalp

| # | First author | Published year | No. of patient | Age, years (mean <u>+</u> SD) | Disease | Pain duration of patients | Study type | Outcome parameters | Results |
|---|-----------------|-------------------|----------------------------|--|---------------|------------------------------------|--|------------------------------------|--|
| 1 | Lin (16) | 2022 | 35 (tACS: sham = 18:17) | tACS: 48.3 ± 13.6 Sham: 48.9 ± 12.3 | Fibromyalgia | ≥3 months | RCT | NRS, FIQ, BAI, BDI-II, and PSQI | All the measured outcomes were not significantly different between the tACS and sham stimulation groups. |
| 2 | Ahn (13) | 2019 | 20 | Age range: 18–65, no information on mean | Low back pain | ≥5 months | Randomized, double-blind, crossover design | DVPRS, ODI, and EEG | The DVPRS score was significantly lower after tACS than after sham stimulation, but the ODI was not. The increase in alpha oscillations was significantly higher after tACS compared to sham stimulation. |
| 3 | Prim (17) | 2019 | 20 | 43.0 ± 13.4 | Low back pain | ≥6 months | Randomized, double-blind, crossover design | DVPRS | No significant difference was found between tACS and sham stimulation. |
| 4 | Antal (14) | 2020 | 25 (tACS: sham = 16:9) | tACS: 31.1 ± 8.9 Sham: 28.1 ± 10.5 | Migraine | ≥6 months | RCT | NRS | - The reduction of NRS at 2 and 4h after stimulation was significantly higher in the tACS group than in the sham stimulation group. |

TABLE 1 Characteristics of the included studies.

tACS, Transcranial alternating current stimulation; SD, Standard deviation; RCT, Randomized controlled trial; NRS, Numeric rating scale; FIQ, Fibromyalgia impact questionnaire; BAI, Beck Anxiety Inventory; PSQI, Pittsburgh Sleep Quality Index; DVPRS, Defense and Veterans Pain Rating Scale; ODI, Oswestry Disability Index; and EEG, electroencephalogram.

pain, tingling, itching, ringing/buzzing noise, burning sensation, local redness, sleepiness, trouble concentrating, improved mood, worsening of mood, dizziness, and flickering lights, with numeric scores. The significant difference in score for each side effect was not shown between tACS and sham stimulation.

Migraine

In 2020, Antal et al. (14) recruited 40 patients with chronic migraine (pain duration: \geq 6 months), and they were randomly allocated to the tACS (25 patients) and sham stimulation (15 patients) groups. Among these patients, 25 patients—16 in the tACS group and nine in the sham stimulation group—completed the study. The study was conducted over the course of 6 weeks. Patients were asked to write a headache diary during the study period. During the study, the

frequency of the migraine attacks, duration of the pain, and use of analgesics were recorded. The pain degree was also measured with NRS at the onset of a migraine attack as well as 1, 2, 4, 8, 24, and 48 h thereafter. tACS or sham stimulation was applied by the patient at home. The stimulation was applied at the beginning of the migraine attack. The stimulating electrode (4cm×4cm) was placed over the occipital lobe (Oz) and the return electrode $(5 \text{ cm} \times 7 \text{ cm})$ over the Cz electrode position. tACS with 0.4 mA was applied for 15 min. During the study, 65 migraine attacks were treated in 16 patients in the tACS group (mean: 4.06 attacks/patient) and 37 in nine patients in the sham stimulation group (mean: 4.11 attacks/patient). In the tACS group, 27 of the 65 migraine attacks were treated with oral medications within 2 h after the stimulation, compared to 14 of the 37 attacks in the sham stimulation group. During the migraine attacks without taking oral medications, the pain disappeared within 2h post-stimulation in 14 of the 38 attacks in the tACS group but in none of the 23 attacks in the

| # | First author | Simulation site | Intensity (mA) | Duration (min) | Frequency (Hz) | No. of sessions | Combined treatments with tACS | Treatment received by control group |
|---|-----------------|------------------------------|-------------------|-------------------|-------------------|--|--|--|
| 1 | Lin (16) | M1 | 1 | 20 | 50 | 10 | No combined treatment. | Sham stimulation |
| 2 | Ahn (13) | Bilateral F-lobe (F3, F4) | 1 | 40 | 10 | 1 per study arm | No combined treatment. | Sham stimulation |
| 3 | Prim (17) | M1 | 1 | 40 | 10 | 1 per study arm | No combined treatment. | Sham stimulation |
| 4 | Antal (14) | O-lobe (Oz) | 0.4 | 15 | 140 | 1 (at the beginning of the migraine attack) | The included patients were allowed to take their regular acute migraine medications | Sham stimulation and regular acute migraine medications |

TABLE 2 Application methods for tACS treatment and combined treatments with tACS.

tACS, Transcranial alternating current stimulation; M1, Primary motor cortex; F-lobe, Frontal lobe; and O-lobe, Occipital lobe.

sham stimulation group, with a statistically significant intragroup difference. The rate of terminated migraine attacks that did not require acute rescue medication was significantly higher in the tACS group (21.5%) than in the sham stimulation group (0%). The pain severity measured with NRS was significantly lower after tACS than after sham stimulation in 2 and 4 h after the stimulation.

Risk of Bias

All four included studies had a low risk of bias in the domains of allocation concealment, blinding of participants and personnel, and selective reporting (Figure 2). In random sequence generation, three studies had a low risk of bias. In the domain of blinding outcome assessment, only one study had a low risk of bias, and in the domain of incomplete outcome data, two studies had a low risk of bias. Three studies had a low risk of bias in the domain of other biases. Among the 28 domains across all four included studies, 21 domains (75.0%) were determined to be low risk. The inter-rater agreement for the determination of potential bias of each study was 0.900 (p < 0.001) according to the kappa index.

Discussion

In this review of tACS for chronic pain, we found four published articles in that met our inclusion criteria (13, 14, 16, 17). The patients included in the previous studies had fibromyalgia in one study (16), LBP in two studies (13, 17), and migraine in one study (14).

Patients with chronic pain exhibit impaired alpha oscillations (13, 19). It is known that pain perception suppresses alpha oscillations (13, 19). Previous studies found that the amplitude of alpha oscillations in the brain was negatively correlated with the severity of chronic pain (20–22). tACS can modulate neural oscillations by applying oscillating electrical currents (10–12). The enhanced alpha oscillations by tACS can be suggested to induce pain relief. Additionally, in patients with chronic pain, abnormal activation of the thalamic nuclei, insula, anterior cingulate, and sensory and prefrontal cortices was observed during pain processing (23, 24). The previous studies using EEG found increased theta rhythm mainly located in the anterior cingulate and frontal cortex, which are part of the thalamocortical circuit. The thalamocortical circuit plays a crucial role in processing and



transmitting pain signals in the human brain (25, 26). Abnormal activation of the thalamocortical circuit is considered a key pathology inducing the development of chronic pain (25, 26). Therefore, chronic pain is interpreted as the result of thalamocortical dysrhythmia (25). Low-intensity alternating currents produced by tACS could modulate abnormal neural activation within the thalamocortical circuit, which is supposed to be helpful for alleviating chronic pain (15).

However, contrary to our expectations, the results of our study that integrated the findings of four previous studies were conflicting (13, 14, 16, 17). In the study on fibromyalgia (16), it did not show a better pain-reducing effect of tACS compared with sham stimulation

(16). The two studies on LBP showed opposite results (13, 17). The study of Ahn et al. (13) showed a positive pain-reducing effect of tACS, but study of Prim et al. (17) did not find any significant difference between the pain-reducing effect of tACS and that of sham stimulation. Regarding migraine, the study reported that tACS was helpful for terminating migraine attacks and reducing pain severity during migraine attacks (14). The conflicting results hinder the conclusion of the effectiveness of tACS for controlling chronic pain.

Responses to tACS can vary among individuals. Factors such as the brain anatomy, exact placement of electrodes, and brain state during stimulation would influence the pain-reducing effect of tACS (27). Also, patients suffering from pain exhibit a wide range of pain patterns and characteristics. The individual variation in tACS effects might have contributed to the conflicting results in previous studies.

Additionally, even if the previous studies demonstrated a positive pain-reducing effect of tACS (13, 14), patients with LBP reported only immediate effects after tACS sessions (13). The pain relief effect of tACS in patients with migraines lasted only 24–48 h following tACS treatment (14). The long-term effect of tACS was not reported or evaluated in the previous studies. Therefore, studies investigating the effect of tACS on controlling chronic pain are required.

In the previous studies, the number of stimulation sessions varied in each study. The study of Lin et al. (16) applied tACS with 10 sessions, but the other studies used tACS with a single session (13, 14, 17). Also, the brain area to which tACS was applied and the intensity of current stimulation varied across the previous studies (13, 14, 16, 17). Further research should be conducted to establish the most effective tACS treatment protocol for controlling chronic pain.

In this review, we investigated the effectiveness of tACS in controlling chronic pain. We reviewed four studies (13, 14, 16, 17), among which two reported a positive effect on pain control (13, 14), while the remaining two studies reported negative results (16, 17). Furthermore, even if the positive pain-reducing effect of tACS was reported in two studies, it was only an immediate or short-term pain-relieving effect (13, 14). We think that there is still insufficient research to draw a conclusive judgment on the effects of tACS on controlling chronic pain. For a definitive conclusion, more studies across various chronic pain-related diseases are required. Also, studies for determining the optimal stimulation area, intensity, duration, and frequency for tACS treatment should be conducted in the future.

References

1. Chang MC. The blind spot and challenges in pain management. J Yeungnam Med Sci. (2022) 39:179–80. doi: 10.12701/jyms.2022.00339

2. Lee JH, Chang MC. Some suggestions for pain physicians working in real-world clinical settings. *J Yeungnam Med Sci.* (2023) 40:S123–4. doi: 10.12701/jyms.2023.00255

3. Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, et al. Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. *MMWR Morb Mortal Wkly Rep.* (2018) 67:1001–6. doi: 10.15585/mmwr.mm6736a2

4. Garland EL. Pain processing in the human nervous system: a selective review of nociceptive and biobehavioral pathways. *Prim Care.* (2012) 39:561–71. doi: 10.1016/j. pop.2012.06.013

5. Sarnthein J, Jeanmonod D. High thalamocortical theta coherence in patients with neurogenic pain. *NeuroImage*. (2008) 39:1910-7. doi: 10.1016/j.neuroimage.2007.10.019

 Sarnthein J, Stern J, Aufenberg C, Rousson V, Jeanmonod D. Increased EEG power and slowed dominant frequency in patients with neurogenic pain. *Brain.* (2006) 129:55–64. doi: 10.1093/brain/awh631

 Stern J, Jeanmonod D, Sarnthein J. Persistent EEG overactivation in the cortical pain matrix of neurogenic pain patients. *NeuroImage*. (2006) 31:721–31. doi: 10.1016/j. neuroimage.2005.12.042

Author contributions

MC: Writing – original draft, Writing – review & editing, Conceptualization, Formal analysis, Project administration, Visualization, Investigation, Methodology, Resources. M-MB: Methodology, Writing – review & editing. MB-R: Formal analysis, Methodology, Validation, Writing – review & editing. SY: Conceptualization, Formal analysis, Project administration, Visualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (no. 00219725).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2023.1323520/ full#supplementary-material

8. Walton KD, Dubois M, Llinás RR. Abnormal thalamocortical activity in patients with complex regional pain syndrome (CRPS) type I. *Pain.* (2010) 150:41–51. doi: 10.1016/j.pain.2010.02.023

9. May ES, Hohn VD, Nickel MM, Tiemann L, Gil Ávila C, Heitmann H, et al. Modulating brain rhythms of pain using transcranial alternating current stimulation (tACS)—a sham-controlled study in healthy human participants. *J Pain.* (2021) 22:1256–72. doi: 10.1016/j.jpain.2021.03.150

10. Antal A, Paulus W. Transcranial alternating current stimulation (tACS). Front Hum Neurosci. (2013) 7:317. doi: 10.3389/fnhum.2013.00317

11. Elyamany O, Leicht G, Herrmann CS, Mulert C. Transcranial alternating current stimulation (tACS): from basic mechanisms towards first applications in psychiatry. *Eur Arch Psychiatry Clin Neurosci.* (2021) 271:135–56. doi: 10.1007/s00406-020-01209-9

12. Wischnewski M, Alekseichuk I, Opitz A. Neurocognitive, physiological, and biophysical effects of transcranial alternating current stimulation. *Trends Cogn Sci.* (2023) 27:189–205. doi: 10.1016/j.tics.2022.11.013

13. Ahn S, Prim JH, Alexander ML, McCulloch KL, Fröhlich F. Identifying and engaging neuronal oscillations by transcranial alternating current stimulation in patients

with chronic low Back pain: a randomized, crossover, double-blind, sham-controlled pilot study. *J Pain*. (2019) 20:277.e1–277.e11. doi: 10.1016/j.jpain.2018.09.004

14. Antal A, Bischoff R, Stephani C, Czesnik D, Klinker F, Timäus C, et al. Low intensity, transcranial, alternating current stimulation reduces migraine attack burden in a home application set-up: a double-blinded, randomized feasibility study. *Brain Sci.* (2020) 10:888. doi: 10.3390/brainsci10110888

15. Bernardi L, Bertuccelli M, Formaggio E, Rubega M, Bosco G, Tenconi E, et al. Beyond physiotherapy and pharmacological treatment for fibromyalgia syndrome: tailored tACS as a new therapeutic tool. *Eur Arch Psychiatry Clin Neurosci.* (2021) 271:199–210. doi: 10.1007/s00406-020-01214-y

16. Lin AP, Chiu CC, Chen SC, Huang YJ, Lai CH, Kang JH. Using high-definition transcranial alternating current stimulation to treat patients with fibromyalgia: a randomized double-blinded controlled study. *Lifestyles*. (2022) 12:1364. doi: 10.3390/ life12091364

17. Prim JH, Ahn S, Davila MI, Alexander ML, McCulloch KL, Fröhlich F. Targeting the autonomic nervous system balance in patients with chronic low Back pain using transcranial alternating current stimulation: a randomized, crossover, double-blind. *J Pain Res.* (2019) 12:3265–77. doi: 10.2147/JPR.S208030

18. Higgins JPT, Green S (2011). Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Available at: http://handbook-5-1.cochrane.org/

19. Arendsen LJ, Henshaw J, Brown CA, Sivan M, Taylor JR, Trujillo-Barreto NJ, et al. Entraining alpha activity using visual stimulation in patients with chronic musculoskeletal pain: a feasibility study. *Front Neurosci.* (2020) 14:828. doi: 10.3389/fnins.2020.00828

20. Babiloni C, Brancucci A, Del Percio C, Capotosto P, Arendt-Nielsen L, Chen AC, et al. Anticipatory electroencephalography alpha rhythm predicts subjective perception of pain intensity. *J Pain*. (2006) 7:709–17. doi: 10.1016/j.jpain.2006.03.005

21. Ploner M, Sorg C, Gross J. Brain rhythms of pain. Trends Cogn Sci. (2017) 21:100–10. doi: 10.1016/j.tics.2016.12.001

22. Tu Y, Zhang Z, Tan A, Peng W, Hung YS, Moayedi M, et al. Alpha and gamma oscillation amplitudes synergistically predict the perception of forthcoming nociceptive stimuli. *Hum Brain Mapp*. (2016) 37:501–14. doi: 10.1002/hbm.23048

23. Burgmer M, Gaubitz M, Konrad C, Wrenger M, Hilgart S, Heuft G, et al. Decreased gray matter volumes in the cingulo-frontal cortex and the amygdala in patients with fibromyalgia. *Psychosom Med.* (2009) 71:566–73. doi: 10.1097/PSY.0b013e3181a32da0

24. Staud R, Craggs JG, Perlstein WM, Robinson ME, Price DD. Brain activity associated with slow temporal summation of C-fiber evoked pain in fibromyalgia patients and healthy controls. *Eur J Pain*. (2008) 12:1078–89. doi: 10.1016/j.ejpain.2008.02.002

25. Gücer G, Niedermeyer E, Long DM. Thalamic EEG recordings in patients with chronic pain. J Neurol. (1978) 219:47–61. doi: 10.1007/BF00313368

26. Llinás RR, Ribary U, Jeanmonod D, Kronberg E, Mitra PP. Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. *Proc Natl Acad Sci U S A*. (1999) 96:15222–7. doi: 10.1073/pnas.96.26.15222

27. Miyaguchi S, Otsuru N, Kojima S, Yokota H, Saito K, Inukai Y, et al. Gamma tACS over M1 and cerebellar hemisphere improves motor performance in a phase-specific manner. *Neurosci Lett.* (2019) 694:64–8. doi: 10.1016/j.neulet.2018.11.015